Stopping renin-angiotensin system inhibitors in chronic kidney disease: Predictors of response

Nephron - Clinical Practice

Volumn 119, Issue 4, 2011, Pages

  Gonçalves, Anderson Roman ^a   Khwaja, Arif ^b   Ahmed, Aimun K ^b   El Kossi, Mohsen ^b   El Nahas, Meguid ^b  

^a UNIVERSITY OF JOINVILLE REGION   (Brazil)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Chronic kidney disease; Predictors; Renin angiotensin system inhibitors

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RECEIVER OPERATING CHARACTERISTIC; RENAL REPLACEMENT THERAPY; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; CREATININE; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERKALEMIA; HYPERTENSION; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; MALE; MIDDLE AGED; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; ROC CURVE; TREATMENT OUTCOME;

EID: 82955217247     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000331072     Document Type: Review

References (28)

1. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: 11-13.
2. National Collaborating Centre for Chronic Conditions: Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care. London, Royal College of Physicians, 2008.
3. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131-140. (Pubitemid 43076710)
4. Levin A, Djurdjev O, Beaulieu M, Er L: Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis 2008; 52: 661-671.
5. Ruggenenti P, Perna A, Remuzzi G: ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post-hoc analysis of the REIN trial results. J Am Soc Nephrol 2001; 12: 2832-2837. (Pubitemid 33115432)
6. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
7. Kent DM, Jafar TH, Hayward RA, Tighiouart H, Landa M, de Jong P, de Zeeuw D, Remuzzi G, Kamper AL, Levey AS, for the AIRPD Study Group: Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 2007; 18: 1959-1965.
8. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL, for the African American Study of Kidney Disease and Hypertension Study Group: the relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2005; 165: 947-953. (Pubitemid 40563243)
9. Obi Y, Kimura T, Nagasawa Y, Yamamoto R, Yasuda K, Sasaki K, Kitamura H, Imai E, Rakugi H, Isaka Y, Hayashi T: Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort. Clin J Am Soc Nephrol 2010; 5: 1558-1565.
10. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G: Renoprotective properties of ACE inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-364. (Pubitemid 29355751)
11. Suissa S, Hutchinson T, Brophy JM, Kezouh A: ACE inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006; 69: 913-919.
12. Miao Y, Dobre D, Lambers Heerspink H, Brenner B, Cooper M, Parving HH, Shahinfar S, Grobbee D, de Zeeuw D: Increased serum potassium affects renal outcomes: a post-hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia 2011; 54: 44-50.
13. Bakris GL: Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons? Ann Intern Med 2009; 150: 731-733.
14. O'Hare AM, Choi AI, Bertenthal D, Bacchetti P, Garg AX, Kaufman JS, Walter LC, Mehta KM, Steinman MA, Allon M, McClellan WM, Landefeld CS: Age affects outcomes in chronic kidney disease. J Am Soc Nephrol 2007; 18: 2758-2765. (Pubitemid 47531203)
15. O'Hare AM, Kaufman JS, Covinsky KE, Landefeld CS, McFarland LV, Larson EB: Current guidelines for using angiotensinconverting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? Ann Intern Med 2009; 150: 717-724.
16. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T, for the ALLHAT Collaborative Research Group: Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker versus a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165: 936-946. (Pubitemid 40563242)
17. Ahmed AK, Kamath NS, El Kossi M, El Nahas AM: The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 2010; 25: 3977-3982.
18. Onuigbo M, Onuigbo N: Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients. Int Urol Nephrol 2008; 40: 233-239.
19. Swets JA: Measuring the accuracy of diagnostic systems. Science 1988; 240: 1285-1293.
20. Brown NJ, Vaughan DE: Angiotensin-converting enzyme inhibitors. Circulation 1998; 97: 1411-1420. (Pubitemid 28182680)
21. Anderson S, Eldadah B, Halter JB, Hazzard WR, Himmelfarb J, Horne FM, Kimmel PL, Molitoris BA, Murthy M, O'Hare AM, Schmader KE, High KP: Acute kidney injury in older adults. J Am Soc Nephrol 2011; 22: 28-38.
22. Hill GS: Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens 2008; 17: 266-270. (Pubitemid 351535929)
23. Zhou XJ, Rakheja D, Yu X, Saxena R, Vaziri ND, Silva FG: The aging kidney. Kidney Int 2008; 74: 710-720.
24. Appel LJ, Wright JT, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X: Intensive bloodpressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363: 918-929.
25. Myers OB, Adams C, Rohrscheib MR, Servilla KS, Miskulin D, Bedrick EJ, Zager PG: Age, race, diabetes, blood pressure, and mortality among hemodialysis patients. J Am Soc Nephrol 2010; 21: 1970-1978.
26. The ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
27. Charytan D, Kuntz RE: The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 2006; 70: 2021-2030. (Pubitemid 44863392)
28. Coca SG, Krumholz HM, Garg AX, Parikh CR: Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006; 296: 1377-1384. (Pubitemid 44427424)